127 related articles for article (PubMed ID: 34923193)
1. Upregulated expression of DDX5 predicts recurrence and poor prognosis in breast cancer.
Li K; Zhao G; Yuan H; Zhang J; Li Q; Gong D; Lin P
Pathol Res Pract; 2022 Jan; 229():153736. PubMed ID: 34923193
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of DEAD box helicase 5 and 17 are correlated with the progression and poor prognosis in gliomas.
Luo Q; Que T; Luo H; Meng Y; Chen X; Huang H; Hu R; Luo K; Zheng C; Yan P; Gong J; Fu H; Liu J; Tang Q; Huang G
Pathol Res Pract; 2020 Mar; 216(3):152828. PubMed ID: 32008867
[TBL] [Abstract][Full Text] [Related]
3. DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway.
Wang Z; Luo Z; Zhou L; Li X; Jiang T; Fu E
Cancer Sci; 2015 Oct; 106(10):1303-12. PubMed ID: 26212035
[TBL] [Abstract][Full Text] [Related]
4. Loss of Dicer expression is associated with breast cancer progression and recurrence.
Khoshnaw SM; Rakha EA; Abdel-Fatah TM; Nolan CC; Hodi Z; Macmillan DR; Ellis IO; Green AR
Breast Cancer Res Treat; 2012 Sep; 135(2):403-13. PubMed ID: 22821364
[TBL] [Abstract][Full Text] [Related]
5. HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.
Abdel-Fatah TM; McArdle SE; Johnson C; Moseley PM; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
Br J Cancer; 2014 May; 110(10):2450-61. PubMed ID: 24755885
[TBL] [Abstract][Full Text] [Related]
6. Low expression of DDX5 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma.
Morimachi M; Hirabayashi K; Takanashi Y; Kawanishi A; Saika T; Ueyama Y; Nakagohri T; Nakamura N; Suzuki H; Kagawa T
J Clin Pathol; 2021 Nov; 74(11):741-745. PubMed ID: 33097588
[TBL] [Abstract][Full Text] [Related]
7. DDX5 promotes hepatocellular carcinoma tumorigenesis via Akt signaling pathway.
Xue Y; Jia X; Li L; Dong X; Ling J; Yuan J; Li Q
Biochem Biophys Res Commun; 2018 Sep; 503(4):2885-2891. PubMed ID: 30119889
[TBL] [Abstract][Full Text] [Related]
8. The BMP inhibitor DAND5 in serum predicts poor survival in breast cancer.
Chi Y; Yao L; Hu X; Huang S; Huang N; Li S; Shao Z; Wu J
Oncotarget; 2016 Mar; 7(12):14951-62. PubMed ID: 26908452
[TBL] [Abstract][Full Text] [Related]
9. Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes.
Wang H; Yao J; Zhu Y; Zhan W; Chen X; Shen K
Cancer Med; 2020 Sep; 9(17):6173-6185. PubMed ID: 32657039
[TBL] [Abstract][Full Text] [Related]
10. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.
Shubbar E; Helou K; Kovács A; Nemes S; Hajizadeh S; Enerbäck C; Einbeigi Z
BMC Cancer; 2013 Feb; 13():47. PubMed ID: 23374458
[TBL] [Abstract][Full Text] [Related]
11. CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients.
Kimbung S; Inasu M; Stålhammar T; Nodin B; Elebro K; Tryggvadottir H; Ygland Rödström M; Jirström K; Isaksson K; Jernström H; Borgquist S
Breast Cancer Res; 2020 Nov; 22(1):123. PubMed ID: 33176848
[TBL] [Abstract][Full Text] [Related]
12. NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis.
Wan L; Liu T; Hong Z; Pan Y; Sizemore ST; Zhang J; Ma Z
Breast Cancer Res; 2019 Dec; 21(1):148. PubMed ID: 31856858
[TBL] [Abstract][Full Text] [Related]
13. RNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cells.
Wang D; Huang J; Hu Z
Mol Cell Proteomics; 2012 Feb; 11(2):M111.011932. PubMed ID: 22086602
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of long non-coding RNA CCAT1 is a novel biomarker of poor prognosis in patients with breast cancer.
Zhang XF; Liu T; Li Y; Li S
Int J Clin Exp Pathol; 2015; 8(8):9440-5. PubMed ID: 26464701
[TBL] [Abstract][Full Text] [Related]
15. Expression of microRNA-497 and its prognostic significance in human breast cancer.
Wang S; Li H; Wang J; Wang D
Diagn Pathol; 2013 Oct; 8():172. PubMed ID: 24143964
[TBL] [Abstract][Full Text] [Related]
16. High expression of ALDOA and DDX5 are associated with poor prognosis in human colorectal cancer.
Dai L; Pan G; Liu X; Huang J; Jiang Z; Zhu X; Gan X; Xu Q; Tan N
Cancer Manag Res; 2018; 10():1799-1806. PubMed ID: 29988738
[TBL] [Abstract][Full Text] [Related]
17. PAK5 promotes RNA helicase DDX5 sumoylation and miRNA-10b processing in a kinase-dependent manner in breast cancer.
Li Y; Xing Y; Wang X; Hu B; Zhao X; Zhang H; Han F; Geng N; Wang F; Li Y; Li J; Jin F; Li F
Cell Rep; 2021 Dec; 37(12):110127. PubMed ID: 34936874
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
Roberts MC; Miller DP; Shak S; Petkov VI
Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
[TBL] [Abstract][Full Text] [Related]
19. HAGE, the helicase antigen as a biomarker for breast cancer prognosis (WO2013144616).
Wiese M; Pajeva IK
Expert Opin Ther Pat; 2014 Jun; 24(6):723-5. PubMed ID: 24766479
[TBL] [Abstract][Full Text] [Related]
20. The value of Nottingham grade in breast cancer re-visited in the Sri Lankan setting.
Peiris H; Mudduwa L; Thalagala N; Jayatialake K
Malays J Pathol; 2017 Aug; 39(2):141-148. PubMed ID: 28866695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
